Eli Lilly has begun eliminating mandated price breaks for a few dozen hospitals enrolled in the federal 340B drug discount program, making good on a threat it issued earlier this month after those facilities failed to provide comprehensive claims data. The drugmaker says the step is designed to eliminate what it calls duplicate discounts; hospital trade groups call the move unlawful and are urging Congress to intervene.
What the 340B Program Is — and What Lilly Is Requiring
The 340B program is a federal drug discount program under which certain hospitals receive mandated price breaks from drug manufacturers. Lilly announced in January that it would require participating hospitals to hand over claims data as a condition of continuing to receive those discounts, with the policy taking effect on Feb. 1. The company's rationale is that the data allows it to verify that discounts are not being applied more than once to a single transaction — what it refers to as a duplicate discount.
How Compliance Broke Down
When Lilly issued its warning earlier this month, the company said more than 2,300 hospitals had already provided the requested claims data. A far larger group had not: Lilly indicated that up to 1,000 hospitals remained noncompliant. The company directed particular enforcement pressure toward roughly 50 larger hospital systems, sending follow-up letters asking them to provide data before facing consequences.
Those hospitals did not comply. Lilly has now begun removing 340B price breaks from noncompliant facilities — a move that currently covers a few dozen hospitals, predominantly larger systems.
Hospitals Call the Action Illegal
Hospital trade groups are not treating Lilly's enforcement as a routine compliance matter. They argue the move is unlawful, contending that a drug manufacturer cannot attach new data-sharing conditions to a federally mandated discount program and then strip those discounts from hospitals that decline to meet them. The groups are calling on Congress to step in and block what they characterize as an unauthorized rewrite of the program's terms.
Lilly has maintained that its policy is a necessary check against duplicate discounting. With enforcement now in effect for a first group of noncompliant hospitals, the dispute has moved past the warning stage into a direct conflict over access to federally required drug pricing.